Skip to main content
SpringerLink
Log in

Der Hodentumor: gestern – heute – morgen

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Albers P, Siener R, Kliesch S et al. (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 21: 1505–1512

    Article  PubMed  Google Scholar 

  2. Baniel J, Foster RS, Rowland RG et al. (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152: 424–427

    PubMed  Google Scholar 

  3. Baniel J, Foster RS, Rowland RG et al. (1995) Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153: 976–80

    Article  PubMed  Google Scholar 

  4. Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland/ Atlas of Cancer Mortality in Germany, 3rd edn. Springer, Berlin Heidelberg New York

  5. Bentzen SM (2005) Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 77: 227–230

    Article  PubMed  Google Scholar 

  6. Bentzen SM (2005) Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6: 112–117

    Article  PubMed  Google Scholar 

  7. Beyer J, Kramar A, Mandanas R et al. (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14: 2638–2645

    PubMed  Google Scholar 

  8. Bokemeyer C, Kollmannsberger C, Meisner C et al. (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17: 3450–3456

    PubMed  Google Scholar 

  9. Bray F, Richiardi L, Ekbom A et al. (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118: 3099–3111

    Article  PubMed  Google Scholar 

  10. Cabot H, Berkson J (1939) Neoplasms of the testis: a study of the results of orchidectomy, with and without irradiation. N Engl J Med 220: 192–195

    Google Scholar 

  11. Cullen M (1991) Management of stage I nonseminoma: surveillance and chemotherapy. In: Horwich A (ed) Testicular cancer, investigation and management. Chapman & Hall, London, pp 146–166

  12. Donohue JP, Thornhill JA, Foster RS et al. (1993) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol 71: 326–335

    PubMed  Google Scholar 

  13. Earle JD, Bagshaw MA, Kaplan HS (1973) Supervoltage radiation therapy of the testicular tumors. Am J Roentgenol 117: 653–661

    Google Scholar 

  14. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and Genetics. Tumours of the urinary system and male genital organs. WHO classification of tumours. IARC Press, Lyon

  15. Einhorn LH, Donohue JP (1977) Cis-diammedichloroplatinum, vinblastin, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 87: 293–298

    PubMed  Google Scholar 

  16. Einhorn L (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci USA 99: 4592–4595

    Article  PubMed  Google Scholar 

  17. Fritz A, Percy C, Jack A et al. (2000) International Classification of Diseases for Oncology (ICD-O), 3rd edn. WHO, Geneva

  18. George DW, Foster RS, Hromas RA et al. (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21: 113–22

    Article  PubMed  Google Scholar 

  19. Gerl A, Clemm C, Schmeller N et al. (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8: 41–47

    Article  Google Scholar 

  20. Gietema JA, Meinardi MT, Sleifer DT et al. (2002) Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 13: 1616–1620

    Article  PubMed  Google Scholar 

  21. Hartmann M, Dieckmann KP, Loy V (1998) Hodentumoren. In: Weißbach L, Miller K (Hrsg) Deutsche Krebsgesellschaft: Diagnostische und therapeutische Standards in der urologischen Onkologie. Zuckschwerdt, München Bern, pp 65–91

  22. Heidenreich A, Weissbach L, Höltl W et al. (2001) Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 166: 2161–2165

    Article  PubMed  Google Scholar 

  23. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603

    PubMed  Google Scholar 

  24. Kollmannsberger C, Mayer F, Pressler H et al. (2002) Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 95: 301–308

    Article  PubMed  Google Scholar 

  25. Kollmannsberger C, Nichols C, Bokemeyer C (2006) Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 106: 1217–1226

    Article  PubMed  Google Scholar 

  26. Li MC, Whitmore WF, Golbey R, Grabstald H (1960) Effects of combined drug therapy on metastatic cancer of the testis. J Am Med Assoc 174: 145–153

    Google Scholar 

  27. Link H, Bokemeyer C, Feyer P (Hrsg) (2006) Supportivtherapie bei malignen Erkrankungen. Deutscher Ärzte-Verlag, Köln, ISBN 3-7691-0466-8

  28. Maier JG, Mittemeyer B, Sulak MH (1968) Treatment and prognosis in seminoma of the testis. J Urol 99: 72–78

    PubMed  Google Scholar 

  29. Read G, Stenning SP, Cullen MH et al. (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10: 1762–1768

    PubMed  Google Scholar 

  30. Rorth M (1992) Therapeutic alternatives in clinical stage I nonseminomatous disease. Semin Oncol 19: 190–196

    PubMed  Google Scholar 

  31. Scherer E (1992) Chronik der Strahlentherapie 1900–1960, Bd 1, 1900–1925. Strahlenther Onkol 83 [Suppl]: 83–158

    Google Scholar 

  32. Scherer E (1994) Chronik der Strahlentherapie 1900–1960, Bd 3, 1937–1960. Strahlenther Onkol 85 [Suppl]: 7–296

    Google Scholar 

  33. Schmoll HJ et al. (2004) European Consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann Oncol 15, pp 1377–1399

    Google Scholar 

  34. Souchon R, Schmoll HJ, Krege S, German Testicular Cancer Study Group im Auftrag der Deutschen Krebsgesellschaft (Hrsg) (2002) Leitlinien zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM), 1. Aufl. Zuckschwerdt, München Bern Wien

  35. Weissbach L (1995) Organ preserving surgery of malignant germ cell tumors. J Urol 153: 90–93

    Article  PubMed  Google Scholar 

  36. Werf-Messing van der B (1976) Radiotherapeutic treatment of testicular tumors. Int J Radiat Oncol Biol Phys 1: 235–248

    PubMed  Google Scholar 

  37. Williams SD, Birch R, Irwin L et al. (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435–1440

    PubMed  Google Scholar 

  38. Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1438

    PubMed  Google Scholar 

  39. Wittekind C, Meyer HJ, Bootz F (Hrsg) (2002) TNM-Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York

  40. Wittekind C, Loy V (2003) Pathomorphologische Diagnostik von Hodentumoren. Leitlinien des Berufsverbandes. Berufsverband Deutscher Pathologen und Deutsche Gesellschaft für Pathologie (Hrsg)

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Urologische Universitätsklinik, Hufelandstraße 55, 45122, Essen

    H. Rübben

  2. Institut für Pathologie, Universitätsklinik, Leipzig

    C. Wittekind

  3. Klinik für Strahlentherapie, Allgemeines Krankenhaus, Hagen

    R. Souchon

  4. Klinik für Hämatoonkologie, Universitätsklinik, Hamburg-Eppendorf

    F. Honecker & C. Bokemeyer

  5. Klinik für Urologie, Klinikum, Kassel

    P. Albers

  6. Urologische Universitätsklinik, Ulm

    S. Krege & J. Gschwend

Authors
  1. S. Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Wittekind
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Souchon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Honecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Gschwend
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Krege.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krege, S., Wittekind, C., Souchon, R. et al. Der Hodentumor: gestern – heute – morgen. Urologe 45 (Suppl 4), 169–175 (2006). https://doi.org/10.1007/s00120-006-1114-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1114-7

Search

Navigation